PT  - JOURNAL ARTICLE
AU  - Butterman, Eric
TI  - TMC435 Effective in the Treatment of HCV Genotype 1 Infection
DP  - 2011 Dec 01
TA  - MD Conference Express
PG  - 14--14
VI  - 11
IP  - 12
4099  - http://mdc.sagepub.com/content/11/12/14.short
4100  - http://mdc.sagepub.com/content/11/12/14.full
AB  - Both the PILLAR [TMC435-C205; NCT00882908] and ASPIRE [TMC435-C206; NCT00980330] trials demonstrated that TMC435 (an oral inhibitor of the hepatitis C virus NS3/4A protease) administered once-daily with pegylated interferon alpha-2a (PegIFNa-2a) and ribavirin (RBV) is safe, has potent antiviral activity, and shortens total treatment by 24 weeks compared with PegIFNa-2a/RBV alone.